Renée Victor, Who Voiced Abuelita In Disney's ‘Coco,' Dies
Renée Victor, an American actress best known for her role as Abuelita in the Disney animated film 'Coco' and her performance as Lupita on the Showtime drama 'Weeds,' has died.
The news of Victor's death was confirmed by her representative.
More from Variety
'Coco 2' Set for 2029 Release From Disney and Pixar
'Weeds' Star Elizabeth Perkins Is 'On Board' for Reboot: 'I Loved Working With Mary-Louise Parker'
Justin Kirk Doubts Anyone Wants 'Weeds' Reboot: They're 'Trying to Drag Its Tired Carcass Out'
A San Antonio, Texas native, Victor left the Lone Star State for Los Angeles in the '60s to start her budding career in entertainment. She started in the music business as a singer for popular acts and was a salsa and tango teacher on the side. Victor helped bring prominent Latin musicians like Perez Prado and Xavier Cugat to American music fans.
From 1963 to 1973, Victor brought her own spin to the Latin music scene and toured with her husband under the title 'Ray & Renée.'
One of her first major TV appearances was as the host of the KTLA program 'Pacesetters,' which followed the Chicano Movement of the '70s. Soon after, she began to transition to film and TV work and joined the Screen Actors Guild in 1973. Her early credits include shows like 'Matlock' and 'Scarecrow and Mrs. King.' On the big screen, she has roles in 'A Night in Old Mexico,' 'The Doctor' and 'The Apostle.'
Some of her other TV credits include 'The Addams Family' animated show, 'The Tony Danza Show,' 'Team Knight Rider,' 'Four Corners,' 'ER,' 'House of Payne,' 'Children's Hospital' and the 'Snowpiercer' TV adaptation. On the film side, Victor appeared in 'The Wonderful Ice Cream Suit,' 'Stuntmen,' 'SuperFly,' 'Confessions of a Shopaholic' and 'Paranormal Activity: The Marked Ones.'
Victor also did voice work for the 'Elder Scrolls' series of games, with roles in 2011's 'Skyrim' and the recently released 'Oblivion Remastered.'
Best of Variety
What's Coming to Netflix in June 2025
New Movies Out Now in Theaters: What to See This Week
'Harry Potter' TV Show Cast Guide: Who's Who in Hogwarts?
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
11 minutes ago
- Forbes
Employers Reluctant To Cover Obesity Meds, Lower Costs May Change This
A new survey report from the International Foundation of Employee Benefit Plans shows continued reluctance by United States employers to cover glucagon-like peptide-1 drugs for weight loss. Going forward, however, lower net costs may induce better coverage by employers. Makers of GLP-1s for obesity are offering an array of discounts, some to insurers, others directly to patients. The IFEBP first conducted the survey in Oct. 2023 and again in May 2024. In the latest survey released ten days ago, employers revealed that 55% of them provide coverage of GLP-1s for diabetes only, while only 36% provide coverage for both diabetes and weight loss. And of those employers currently offering GLP-1 drug coverage solely for diabetes, just 17% are considering reimbursement of drugs for weight loss. Broadly speaking, the survey responses demonstrate that a large number of employers are still unwilling to reimburse GLP-1s for obesity. The weight loss therapeutics activate the body's receptors for GLP-1 on its own or in combination with GIP. When released by the gut, these natural hormones increase insulin delivery, suppress appetite, slow stomach emptying and increase the feeling of fullness. Perhaps what's driving continued reluctance to cover these products for weight loss is the overall impact that GLP-1s have on employers' pharmacy budgets. GLP-1 drugs used for obesity account for an average of 10.5% of total annual claims in the 2025 survey. In parts of the traditional health plans' market, we observe that some insurers are reconsidering their coverage of GLP-1s. Blue Cross Blue Shield, for example, just announced a reversal in its policy in which some plans offered coverage of GLP-1s for obesity. Starting in January 2026, BCBS will no longer cover these medicines for weight loss across the insurer's standard plans. At the same time, however, the large insurer Cigna announced it will begin capping out-of-pocket costs at $200 per month, starting next month, for patients using the obesity drugs Wegovy (semaglutide) and Zepbound (tirzepatide) through an add-on to its pharmacy benefit management plans. This is aimed at encouraging more employers to offer coverage of the drugs. It's unknown what the net cost to Cigna will be for the medicines. But presumably, the insurer has been able to reach a deal that's favorable financially, meaning a substantial reduction in net costs. It's possible in future that employers decide to revisit their coverage decisions if net costs decrease sufficiently, combined with more data showing the benefits of weight loss drugs when taken consistently and in conjunction with an appropriate dietary and exercise regimen. Also, the pharmaceutical firm Novo Nordisk announced last month a new partnership with CVS Caremark, the nation's largest pharmacy benefit manager, which grants coverage of Wegovy over its competitor Zepbound for customers who are insured for obesity medications. It's presumed that CVS was able to negotiate sizable rebates for Wegovy. CVS Caremark said that for insured patients, starting this July, Wegovy and Saxenda (liraglutide) will be the preferred GLP-1 medicines on its largest commercial formularies. This implies fewer access restrictions such as prior authorization, but also lower patient cost-sharing. It's unknown precisely what this means in terms of out-of-pocket costs for patients. But most patients with coverage for obesity drugs have monthly cost-sharing under $100. The arrangements reached by Cigna and CVS could help bring down net prices for employers for popular weight loss medicines. And at the same time, under the Inflation Reduction Act, the federal government is negotiating the prices of the GLP-1s Ozempic (semaglutide) and Wegovy. So-called maximum fair prices will be publicly posted in early 2026. These could reflect even steeper discounts. In addition to what payers are doing, Novo Nordisk is pursuing a direct-to-patient strategy to regain market share it has lost to drug maker Eli Lilly in the lucrative obesity drug market. Here, Novo Nordisk struck a deal in which CVS pharmacy will offer Wegovy for $499 a month for cash-paying customers who aren't insured for the medication. Since the Food and Drug Administration removed the active ingredients semaglutide and tirzepatide from its shortage list, the business model of selling directly at a considerable discount to the consumer has become popular for the two main manufacturers of obesity drugs. In 2024, Eli Lilly adopted a direct-to-consumer strategy for Zepbound, among other products, with its LillyDirect program. This service includes a DTC pharmacy and a referral network of in-person and telehealth clinicians. LillyDirect allows uninsured or underinsured individuals not on Medicaid or Medicare to purchase Zepbound product directly after obtaining the requisite prescription from their doctor. The firm recently extended the range of Zepbound products available through LillyDirect by adding high-dose vials at $499. Rival Novo Nordisk also launched a DTC option, NovoCare Pharmacy, two months ago. Patients not insured in the public sector who wish to have access to Wegovy can acquire the drug for an out-of-pocket cost of $499 per month, provided they have a prescription and make use of a designated specialty pharmacy. And, since the end of April, customers also pay a $499 monthly subscription when they obtain Wegovy from Ro and LifeMD, and $599 at Hims & Hers. While employers aren't yet reimbursing weight loss drugs en masse, significantly reduced net costs could affect their future coverage decisions.
E&E News
12 minutes ago
- E&E News
Meet the youth challenging Trump on climate
Eva Lighthiser, 19, lives in Livingston, Montana, and is accustomed to milelong coal trains rumbling through town and blowing coal dust across the city. In 2023, she was a plaintiff in a youth-led lawsuit that sought to force her state to tackle climate change. Now, she's the lead challenger in Lighthiser v. Trump, a new climate lawsuit that accuses President Donald Trump of violating the Constitution by issuing a trio of executive orders that fast track fossil fuel development. 'Every place is going to be affected by this administration and it's very concerning to see what that will look like moving forward,' Lighthiser said in an interview. Advertisement The case, filed last week in the U.S. District Court for the District of Montana, argues that Trump's executive orders will worsen climate change and increase health dangers by declaring a 'national energy emergency' and directing the government to 'unleash American energy.'
News24
14 minutes ago
- News24
Boobs, bucks, bling: Jeff Bezos' bride's R11-million hen party
Be among those who shape the future with knowledge. Uncover exclusive stories that captivate your mind and heart with our FREE 14-day subscription trial. Dive into a world of inspiration, learning, and empowerment. You can only trial once. Start your FREE trial now
